No Greater Incidence or Worsening of Cardiac Valve Regurgitation with Somatostatin Analog Treatment of Acromegaly

Abstract

The incidence of valve regurgitation did not change over 12 months of treatment with somatostatin analogs, and most cases were physiologic or mild in severity. There was no significant difference between somatostatin analogs in the risk of developing new/worsening valve regurgitation or significant regurgitation after 1 yr.